Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors

Endocrine-Related Cancer

Volumn 15, Issue 1, 2008, Pages 257-266

  Moreno, Amy ^a   Akcakanat, Argun ^a   Munsell, Mark F ^a   Soni, Alpana ^a   Yao, James C ^a   Meric Bernstam, Funda ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OCTREOTIDE; PROTEIN KINASE B; RAPAMYCIN; SOMATOSTATIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOID; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; FEEDBACK SYSTEM; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; PROTEIN PHOSPHORYLATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CARCINOID TUMOR; CELL PROLIFERATION; CELLS, CULTURED; HUMANS; MALE; MICE; MICE, INBRED BALB C; NEUROENDOCRINE TUMORS; OCTREOTIDE; PHOSPHORYLATION; PROTEIN KINASES; SIGNAL TRANSDUCTION; SIROLIMUS; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 41349119602     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-07-0202     Document Type: Article

References (30)

1. Akcakanat A, Singh G, Hung MC & Meric-Bernstam F 2007 Rapamycin regulates the phosphorylation of Rictor. Biochemical and Biophysical Research Communications 362 330-333.
2. Celinski SA, Fisher WE, Amaya F, Wu YQ, Yao Q, Youker KA & Li M 2003 Somatostatin receptor gene transfer inhibits established pancreatic cancer xenografts. Journal of Surgical Research 115 41-17.
3. Charland S, Boucher MJ, Houde M & Rivard N 2001 Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen-activated protein (MAP) kinase activation in normal and tumoral pancreatic acinar cells. Endocrinology 142 121-128.
4. Dancey JE 2006 Therapeutic targets: MTOR and related pathways. Cancer Biology and Therapy 5 1065-1073.
5. Dogliotti L, Tampellini M, Stivanello M, Gorzegno G & Fabiani L 2001 The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: comparison with standard subcutaneous octreotide therapy. Annals of Oncology 12 S105-S109.
6. Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, Le L, Oza A, Nicklee T, Ho J et al. 2006 A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. British Journal of Cancer 95 1148-1154.
7. Duran I, Salazar R, Casanovas O, Arrazubi V, Vilar E, Siu L, Yao J & Tabernero J 2007 New drug development in digestive neuroendocrine tumors. Annals of Oncology 18 1307-1313.
8. Evers BM, Gomez G, Townsend CM Jr, Rajaraman S & Thompson JC 1989 Endogenous cholecystokinin regulates growth of human cholangiocarcinoma. Annals of Surgery 210 317-322.
9. Evers BM, Ishizuka J, Townsend CM Jr, Rajaraman S & Thompson JC 1991 Expression of neurotensin messenger RNA in a human carcinoid tumor. Annals of Surgery 214 448-454.
10. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I et al. 2007 Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine 356 2271-2281.
11. Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB & Meric-Bernstam F 2004 Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clinical Cancer Research 10 7031-7042.
12. Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong J, Mills GB, Hung MC & Meric-Bernstam F 2004 Determinants of rapamycin sensitivity in breast cancer cells. Clinical Cancer Research 10 1013-1023.
13. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL et al. 2006 mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Research 66 1500-1508.
14. Perren A, Komminoth P, Saremaslani P, Matter C, Feurer S, Lees JA, Heitz PU & Eng C 2000 Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. American Journal of Pathology 157 1097-1103.
15. Ricci S, Antonuzzo A, Galli L, Ferdeghini M, Bodei L, Orlandini C & Conte PF 2000 Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Annals of Oncology 11 1127-1130.
16. Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, Dandona P & Anthony L 1999 Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. Journal of Clinical Oncology 17 600-606.
17. Shah T, Hochhauser D, Frow R, Quaglia A, Dhillon AP & Caplin ME 2006 Epidermal growth factor receptor expression and activation in neuroendocrine tumours. Journal of Neuroendocrinology 18 355-360.
18. Shi Y, Yan H, Frost P, Gera J & Lichtenstein A 2005 Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Molecular Cancer Therapeutics 4 1533-1540.
19. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H & Khuri FR 2005 Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Research 65 7052-7058.
20. Susini C & Buscail L 2006 Rationale for the use of somatostatin analogs as antitumor agents. Annals of Oncology 17 1733-1742.
21. Theodoropoulou M, Zhang J, Laupheimer S, Paez-Pereda M, Erneux C, Florio T, Pagotto U & Stalla GK 2006 Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Research 66 1576-1582.
22. Tomassetti P, Migliori M, Corinaldesi R & Gullo L 2000 Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Alimentary Pharmacology and Therapeutics 14 557-560.
23. Wang L, Ignat A & Axiotis CA 2002 Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms. Applied Immunohistochemistry and Molecular Morphology 10 139-146.
24. Weckbecker G, Raulf F, Bodmer D & Bruns C 1997 Indirect antiproliferative effect of the somatostatin analog octreotide on MIA PaCa-2 human pancreatic carcinoma in nude mice. Yale Journal of Biology and Medicine 70 549-554.
25. von Wichert G, Jehle PM, Hoeflich A, Koschnick S, Dralle H, Wolf E, Wiedenmann B, Boehm BO, Adler G & Seufferlein T 2000 Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Research 60 4573-4581.
26. Woltering EA, Mamikunian PM, Zietz S, Krutzik SR, Go VL, Vinik AI, Vinik E, O'Dorisio TM & Mamikunian G 2005 Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors. Pancreas 31 392-400.
27. Wymenga AN, Eriksson B, Salmela PI, Jacobsen MB, Van Cutsem EJ, Fiasse RH, Valimaki MJ, Renstrup J, de Vries EG & Oberg KE 1999 Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. Journal of Clinical Oncology 17 1111.
28. Yao JC 2007 Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Practice and Research, Clinical Endocrinology and Metabolism 21 163-172.
29. Yao JC, Phan A, Chang DZ, Wolff RA, Jacobs C, Mares JE, Gupta S, Meric-Bernstam F & Rashid A 2007 Phase II study of RAD001 (everolimus) and depot octreotide (sandostatin LAR) in advanced low grade neuroendocrine carcinoma (LGNET). Journal of Clinical Oncology 25 4503.
30. Zitzmann K, De Toni EN, Brand S, Goke B, Meinecke J, Spottl G, Meyer HH & Auernhammer CJ 2007 The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 85 54-60.